OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza. METHODS: We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 2009, through September 30, 2012. RESULTS: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic (April 3, 2009-August 31, 2010) received NAI treatment compared with 63% (121 of 193) of cases in the postpandemic period (September 1, 2010-September 30, 2012; P < .0001). Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34-1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16-0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die. CONCLUSIONS: Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death.
OBJECTIVE: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza. METHODS: We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 2009, through September 30, 2012. RESULTS: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic (April 3, 2009-August 31, 2010) received NAI treatment compared with 63% (121 of 193) of cases in the postpandemic period (September 1, 2010-September 30, 2012; P < .0001). Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34-1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16-0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die. CONCLUSIONS: Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death.
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Sonya C Tang Girdwood; Tomoyuki Mizuno; Kelli A Krallman; Laura A Benken; Erin M Stoneman; Toni M Yunger; Hector R Wong; Alexander A Vinks; Jennifer M Kaplan Journal: Pediatr Infect Dis J Date: 2019-12 Impact factor: 2.129
Authors: Patrick S Walsh; David Schnadower; Yin Zhang; Sriram Ramgopal; Samir S Shah; Paria M Wilson Journal: JAMA Pediatr Date: 2022-09-19 Impact factor: 26.796
Authors: Ashley L Fowlkes; Andrea Steffens; Carrie Reed; Jonathan L Temte; Angela P Campbell Journal: Open Forum Infect Dis Date: 2019-04-26 Impact factor: 3.835
Authors: Stella G Muthuri; Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Tarig S A Al Khuwaitir; Adbullah Al Mamun; Ashish P Anovadiya; Eduardo Azziz-Baumgartner; Clarisa Báez; Matteo Bassetti; Bojana Beovic; Barbara Bertisch; Isabelle Bonmarin; Robert Booy; Victor H Borja-Aburto; Heinz Burgmann; Bin Cao; Jordi Carratala; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Marcela Echavarria; Sergio Fanella; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath L Higuera Iglesias; Peter H Hoger; Xiaoyun Hu; Quazi T Islam; Mirela F Jiménez; Amr Kandeel; Gerben Keijzers; Hossein Khalili; Marian Knight; Koichiro Kudo; Gabriela Kusznierz; Ilija Kuzman; Arthur M C Kwan; Idriss Lahlou Amine; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Rita Linko; Pei Liu; Faris Madanat; Elga Mayo-Montero; Allison McGeer; Ziad Memish; Gokhan Metan; Auksė Mickiene; Dragan Mikić; Kristin G I Mohn; Ahmadreza Moradi; Pagbajabyn Nymadawa; Maria E Oliva; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Fernando P Polack; Barbara A Rath; Alejandro H Rodríguez; Elena B Sarrouf; Anna C Seale; Bunyamin Sertogullarindan; Marilda M Siqueira; Joanna Skręt-Magierło; Frank Stephan; Ewa Talarek; Julian W Tang; Kelvin K W To; Antoni Torres; Selda H Törün; Dat Tran; Timothy M Uyeki; Annelies Van Zwol; Wendy Vaudry; Tjasa Vidmar; Renata T C Yokota; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam Journal: Lancet Respir Med Date: 2014-03-19 Impact factor: 30.700